CTD blocks the G2/M phase in breast cancer cells by inhibiting the activation of mesenchymal epithelial transition factor (Met)/Sarcoma (Src)/protein kinase B (Akt 2) (Du, 2019) and reducing the expression of matrix metalloproteinase (MMP)-2 and MMP-9 (Gu et al., 2017). Here, AKT1 is linked to breast carcinoma.